PF-Atlas › Clinical Trials › NCT03711162
A Clinical Study to Test How Effective and Safe GLPG1690 is for Subjects With Idiopathic Pulmonary Fibrosis When Used Together With Standard of Care
GLPG1690 · Phase 3
Registry ID
NCT03711162
Phase
Phase 3
Status
Terminated
Drug / intervention
GLPG1690
Sponsor
Lakefront Biotherapeutics NV
Start
2018-11-28
About this trial
GLPG1690 is evaluated in NCT03711162, a Phase 3 idiopathic pulmonary fibrosis study sponsored by Lakefront Biotherapeutics NV. Current status: Terminated.
Explore related
Medical disclaimer. This page summarizes public trial data for NCT03711162 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.